Publications by authors named "Z Van De Wyngaert"
Article Synopsis
- Angioimmunoblastic T-cell lymphoma (AITL) is a type of cancer with a poor response to traditional chemotherapy, featuring a low median survival rate and common relapses.
- A study tested a combination of the drug 5-azacytidine and nivolumab (an anti-PD-1 therapy) in nine patients with AITL, finding it to be well-tolerated and effective, with a 78% overall response rate.
- These promising results suggest that this treatment combination may be a safer and more effective option, warranting further research to establish its efficacy in larger trials.
We evaluated the impact of early recovery of mucosal-associated invariant T cells (MAIT) and gamma-delta (γδ) T cells, especially Vδ2 T cells, on the clinical outcomes of 76 patients who underwent allogeneic hematopoietic cell transplantation (allo-HCT). MAIT cells were identified at day 20-30 post-transplant using flow cytometry and defined as CD3 TCRVα7.2CD161.
View Article and Find Full Text PDFArticle Synopsis
- * A low absolute lymphocyte count (ALC) on day +30 post-transplant was associated with a higher risk of reactivation (68%), while adding antithymocyte globulin (ATG) to GvHD prophylaxis did not significantly affect HHV6 reactivation rates.
- * Patients with HHV6 reactivation experienced delayed platelet recovery and an increased risk of acute GvHD, but their overall
Article Synopsis
- - The case discusses a patient with relapsed IgA and lambda free light chain multiple myeloma who was on dialysis and treated with elranatamab, a bispecific antibody.
- - The treatment was found to be feasible even with the patient's severe kidney impairment, and it did not result in any unexpected side effects.
- - It highlights the importance of monitoring for infectious risks in patients who are both immunocompromised and have renal issues.